Evidence map›Paper›PMID 38061500›Full record

ArticleInternational journal of pharmaceutics2024

Development of uniform fenofibrate-loaded biodegradable microparticle by membrane emulsification.

Tuo Meng, Hadi Sudarjat, Mohammad Momin, Jian-Xing Ma, Qingguo Xu

Abstract read
In one paragraph

Article in International journal of pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tuo MengDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Hadi SudarjatDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Mohammad MominDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Jian-Xing MaDepartment of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Qingguo XuDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA; Department of Ophthalmology, Virginia Commonwealth University, Richmond, VA 23298, USA; Center for Pharmaceutical Engineering, and Institute for Structural Biology, Drug Discovery & Development (ISB3D), Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA. Electronic address: qxu@vcu.edu.

Funding

Sustained release of fenofibrate for the treatment of diabetic retinopathyR01EY033477 · NEI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Jian-Xing Jay Ma, QINGGUO XU · 2022 to 2026
$2.7M
New method to treat or prevent corneal graft rejectionR01EY027827 · NEI · VIRGINIA COMMONWEALTH UNIVERSITY · PI XU, QINGGUO · 2017 to 2021
$2.0M
NEI NIH HHS R01 EY027827NEI NIH HHS R01 EY033477
6 · The paper itself

Abstract

Fenofibrate has shown therapeutic effects on diabetic retinopathy. However, fenofibrate can be rapidly cleared from the eye after a single intravitreal injection. Here, we aim to develop fenofibrate loaded PLGA microparticles (Feno-MP) with high drug loading and sustained in vitro release up to 6 months suitable for intravitreal injection. First, orthogonal array experimental design was applied for formulation optimization. The selected formulation parameters were used to formulate Feno-MP using homogenization method and direct membrane emulsification method. Both methods generated Feno-MP with high drug loading and sustained in vitro drug release more than 140 days. Unlike the polydisperse Feno-MP prepared using homogenization method, membrane emulsification method generated Feno-MP with uniform size distribution. By controlling the membrane pore size, 1.5 µm, 8 µm and 16 µm Feno-MP were formulated and we found that larger Feno-MP demonstrated higher drug loading, more sustained drug release in vitro with less burst drug release than the smaller Feno-MP. In conclusion, we developed Feno-MP with high drug loading and sustained release profile, and elucidated that changing the particle size could have notable impacts on drug loading and release kinetics. Formulating Feno-MP with uniform size distribution by membrane emulsification method would benefit the batch-to-batch repeatability.

Indexed as

FenofibrateDelayed-Action PreparationsDrug LiberationMicrospheresParticle SizePolylactic Acid-Polyglycolic Acid CopolymerDelayed-Action PreparationsFenofibratePolylactic Acid-Polyglycolic Acid CopolymerFenofibrateHomogenizationIntravitreal drug deliveryMembrane emulsificationOrthogonal array designPLGA microparticle

Identifiers

PMID38061500
PMCPMC10843658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.